(Q38046142)

27 August 2017

5 references

28 September 2019

20 November 2019

27 November 2019

13 December 2019

19 January 2021

Immunogenicity of botulinum toxins (English)

1 reference

27 August 2017

1 reference

28 September 2019

1 reference

20 November 2019

1 reference

27 November 2019

1 reference

13 December 2019

neutralizing antibody

1 reference

19 January 2021

Markus Naumann

1

1 reference

27 August 2017

Lee Ming Boo

series ordinal

2

1 reference

27 August 2017

Alan H Ackerman

series ordinal

3

1 reference

27 August 2017

Conor J Gallagher

series ordinal

4

1 reference

27 August 2017

25 September 2012

1 reference

Journal of Neural Transmission

27 August 2017

1 February 2013

5 references

28 September 2019

20 November 2019

27 November 2019

13 December 2019

19 January 2021

6 references

27 August 2017

28 September 2019

20 November 2019

27 November 2019

13 December 2019

19 January 2021

120

1 reference

27 August 2017

2

1 reference

27 August 2017

275-290

1 reference

https://scigraph.springernature.com/pub.10.1007/s00702-012-0893-9

27 August 2017

0 references

cites work

Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Structural basis of TLR5-flagellin recognition and signaling

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Flagellin as an adjuvant: cellular mechanisms and potential.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Botulinum neurotoxin vaccines: past, present, and future

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

The protein load of therapeutic botulinum toxins

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Clinical use of non-A botulinum toxins: botulinum toxin type B.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Botulinum toxin type B (Myobloc): pharmacology and biochemistry

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Basic immunological aspects of botulinum toxin therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Therapeutic use of botulinum toxins: background and history

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Molecular composition of Clostridium botulinum type A progenitor toxins

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

A double blind trial of botulinum toxin "A" in torticollis, with one year follow up

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Properties and use of botulinum toxin and other microbial neurotoxins in medicine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Incidence and severity of anaphylactoid reactions to colloid volume substitutes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Botulinum A toxin: Dysport improvement of biological availability

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Molecular forms of neurotoxins in proteolytic Clostridium botulinum type B cultures

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Botulinum toxin treatment of spasmodic torticollis.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Long-term botulinum toxin efficacy, safety, and immunogenicity.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

The biochemistry of botulinum toxin type B.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Efficacy and Safety of Botulinum Neurotoxin NT 201 in Poststroke Upper Limb Spasticity

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3555308

Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study

3 December 2018

1 reference

12 December 2020

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences

1 reference

12 December 2020

Botulinum toxin type A in refractory chronic migraine: an open-label trial

1 reference

12 December 2020

Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A

1 reference

12 December 2020

Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period

1 reference

12 December 2020

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

1 reference

12 December 2020

Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A

1 reference

12 December 2020

The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans

1 reference

12 December 2020

Development of resistance to botulinum toxin type A in patients with torticollis

1 reference

12 December 2020

On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin

1 reference

12 December 2020

Botulinum A toxins: units versus units

1 reference

12 December 2020

Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke

1 reference

12 December 2020

Xeomin in the treatment of cervical dystonia

1 reference

12 December 2020

Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance

1 reference

12 December 2020

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

1 reference

12 December 2020

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia

1 reference

12 December 2020

The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A

1 reference

12 December 2020

Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure

1 reference

12 December 2020

Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins

1 reference

12 December 2020

Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group

1 reference

12 December 2020

Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study

1 reference

12 December 2020

Response and immunoresistance to botulinum toxin injections

1 reference

12 December 2020

Clinical Correlates of Response to Botulinum Toxin Injections

1 reference

12 December 2020

Stability of the Clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach

1 reference

12 December 2020

Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response

1 reference

12 December 2020

Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?

1 reference

12 December 2020

Serum antibody production to botulinum A toxin

1 reference

12 December 2020

Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses

1 reference

12 December 2020

Phase I comparability of recombinant human albumin and human serum albumin

1 reference

12 December 2020

Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance

1 reference

12 December 2020

Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?

1 reference

12 December 2020

Purification and amino acid composition of type A botulinum neurotoxin

1 reference

12 December 2020

Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients

1 reference

12 December 2020

Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm

1 reference

12 December 2020

10.1007/S00702-012-0893-9

Identifiers

DOI

1 reference

27 August 2017

1 reference

27 August 2017

PubMed publication ID

23008029

1 reference